Last updated 8 days ago
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
1216 patients around the world
Available in Colombia, Mexico, Chile, Argentina, Brazil
Bristol-Myers Squibb
6Research sites
1216Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Confirmed diagnosis of symptomatic multiple myeloma (MM)Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permittedParticipants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria
- Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapySmoldering myeloma, solitary plasmacytoma or nonsecretory myelomaKnown central nervous system/meningeal involvement of MMPrior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years
Sites
Sanatorio Allende (Cerro)
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Fundación Arturo López Pérez
Recruiting
ICOS Instituto Clínico Oncológico del Sur
Recruiting
Hospital Pablo Tobón Uribe
Recruiting
Fundación Oftalmológica de Santander FOSCAL
Recruiting
StudyEXCALIBER Maintenance
SponsorBristol-Myers Squibb
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05827016
